C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes

Annals of Pharmacotherapy

Volumn 37, Issue 11, 2003, Pages 1593-1597

  Cummings, Doyle M ^a,b,c   King, Dana E ^d   Mainous III, Arch G ^e  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Eastern Area Health Education Center   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e NONE

Author keywords

Antiinflammatory drugs; C reactive protein; Diabetes mellitus; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; STATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 0142182460     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D029     Document Type: Article

References (13)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
2. Morrow DA, Ridker PM. Risk factor modification for cardiac disease: C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149-61.
3. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
4. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
6. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
7. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7.
8. Cummings DM, Whetstone L, White D. Rural Eastern Carolina Health (REACH). A model community health improvement program. N C Med J 1999;60:26-8.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, American Diabetes Association, Alexandria, Virginia. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002;25(suppl):S5-S20.
10. Ware JE, Kosinski M, Keller S. A 12-item short-form health survey (SF-12): construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
11. Rifal N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-41.
12. Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF-12 physical and mental health summary scales. 3rd ed. Lincoln, RI: Quality Metric, 1998.
13. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52.